» Articles » PMID: 32482647

Disease Characteristics, Quality of Life, and Work Productivity by Enthesitis Site: Real-world Data From the US Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Overview
Journal J Rheumatol
Specialty Rheumatology
Date 2020 Jun 3
PMID 32482647
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess the effect of clinical enthesitis by body site in patients with psoriatic arthritis (PsA).

Methods: Adults with PsA enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry (March 2013-March 2018) were included. Enthesitis at enrollment was assessed by the Spondyloarthritis Research Consortium of Canada Enthesitis Index and classified by affected sites (upper, lower, or both). Disease activity (e.g., Clinical Disease Activity Index, Clinical Disease Activity Index for PsA), patient-reported outcomes (PRO; e.g., patient-reported pain and fatigue), and work productivity were compared between those with and without enthesitis using - or Wilcoxon rank-sum tests for continuous variables and chi-square or Fisher exact tests for categorical variables. The association of enthesitis with disease activity and PRO measures versus no enthesitis was modeled using multivariable-adjusted linear or logistic regression.

Results: Of 2003 patients with PsA, 391 (19.5%) had enthesitis: 80 (20.5%) in upper sites only; 137 (35.0%) in lower sites only; and 174 (44.5%) in both. Regardless of location, disease activity and PRO were worse in patients with versus without enthesitis. In adjusted models, the presence of enthesitis at any site was significantly associated with worse disease activity versus no enthesitis. Enthesitis in lower or both upper and lower sites was associated with higher pain and fatigue scores and greater work impairment versus no enthesitis.

Conclusion: Patients with clinical enthesitis had worse disease activity regardless of enthesitis location versus those without enthesitis, and patients with enthesitis in lower or both upper and lower sites had worse pain, fatigue, and work impairment.

Citing Articles

The Burden of Work Productivity and Activity Impairment in Patients with Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, and Crohn's Disease.

Janak J, Loughlin A, Moore P, Lemay C, Mease P, Lebwohl M Dig Dis Sci. 2024; 69(8):2784-2795.

PMID: 38811505 DOI: 10.1007/s10620-024-08451-4.


Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis.

Rahman P, McInnes I, Deodhar A, Schett G, Mease P, Shawi M Clin Rheumatol. 2024; 43(5):1591-1604.

PMID: 38472528 PMC: 11018666. DOI: 10.1007/s10067-024-06921-8.


Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic Arthritis.

Curtis J, McInnes I, Rahman P, Gladman D, Peterson S, Yang F Rheumatol Ther. 2024; 11(2):425-441.

PMID: 38386178 PMC: 10920580. DOI: 10.1007/s40744-024-00642-9.


Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials.

Cantini F, Marchesoni A, Novelli L, Gualberti G, Marando F, McDearmon-Blondell E Rheumatology (Oxford). 2024; 63(11):3146-3154.

PMID: 38331400 PMC: 11534117. DOI: 10.1093/rheumatology/keae057.


Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA.

Gaffney K, Gullick N, MacKay K, Patel Y, Sengupta R, Sheeran T Rheumatol Adv Pract. 2023; 7(3):rkad055.

PMID: 37663578 PMC: 10472087. DOI: 10.1093/rap/rkad055.